NASDAQ:STAA - STAAR Surgical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $101.67
  • Forecasted Upside: 33.46 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$76.18
▲ +3.99 (5.53%)

This chart shows the closing price for STAA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New STAAR Surgical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STAA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STAA

Analyst Price Target is $101.67
▲ +33.46% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for STAAR Surgical in the last 3 months. The average price target is $101.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 33.46% upside from the last price of $76.18.

This chart shows the closing price for STAA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in STAAR Surgical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2022Needham & Company LLCReiterated RatingBuy$87.00Low
4/26/2022Canaccord Genuity GroupBoost Price TargetBuy$81.00 ➝ $89.00High
4/26/2022Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$81.00 ➝ $89.00Low
4/23/2022BTIG ResearchReiterated RatingBuy$98.00High
4/8/2022Needham & Company LLCInitiated CoverageBuy$87.00High
3/28/2022BenchmarkUpgradeHold ➝ Buy$97.00High
3/18/2022BTIG ResearchUpgradeNeutral ➝ Buy$98.00High
2/25/2022Canaccord Genuity GroupLower Price TargetBuy ➝ Buy$150.00 ➝ $97.00High
7/8/2021OppenheimerInitiated CoverageMarket Perform$150.00Low
2/8/2021BTIG ResearchReiterated RatingHoldHigh
1/19/2021BenchmarkDowngradeBuy ➝ HoldLow
10/26/2020SidotiDowngradeBuy ➝ NeutralHigh
8/31/2020SidotiUpgradeNeutral ➝ Buy$58.00High
8/28/2020BTIG ResearchReiterated RatingHoldLow
8/6/2020BenchmarkBoost Price TargetBuy$50.00 ➝ $66.00High
7/8/2020StephensBoost Price TargetOverweight$45.00 ➝ $63.00Low
7/6/2020BTIG ResearchReiterated RatingHoldLow
7/6/2020SidotiDowngradeBuy ➝ Neutral$58.00High
6/24/2020BTIG ResearchReiterated RatingBuy ➝ NeutralHigh
6/15/2020Jefferies Financial GroupInitiated CoverageBuy$55.00High
5/6/2020BTIG ResearchReiterated RatingBuy$41.00Medium
3/23/2020StephensLower Price TargetOverweight$56.00 ➝ $37.00Medium
3/10/2020BTIG ResearchReiterated RatingBuy$46.00High
1/2/2020StephensReiterated RatingBuy$56.00Low
12/4/2019BTIG ResearchInitiated CoverageBuy$46.00High
9/24/2018BenchmarkReiterated RatingBuy ➝ Buy$45.00 ➝ $54.00Medium
8/6/2018BenchmarkInitiated CoverageBuy$45.00High
5/3/2018StephensUpgradeEqual Weight ➝ Overweight$13.00 ➝ $21.00High
4/30/2018William BlairUpgradeMarket Perform ➝ OutperformMedium
11/20/2017BenchmarkReiterated RatingBuy ➝ Buy$21.00N/A
10/20/2017BenchmarkBoost Price TargetBuy$13.00 ➝ $15.00N/A
8/14/2017BenchmarkBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.00Medium
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/6/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/5/2022
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
STAAR Surgical logo
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Read More

Today's Range

Now: $76.18
Low: $70.89
High: $76.72

50 Day Range

MA: $64.05
Low: $50.24
High: $76.18

52 Week Range

Now: $76.18
Low: $49.03
High: $163.08

Volume

559,662 shs

Average Volume

445,806 shs

Market Capitalization

$3.64 billion

P/E Ratio

131.35

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of STAAR Surgical?

The following sell-side analysts have issued reports on STAAR Surgical in the last twelve months: Benchmark Co., BTIG Research, Canaccord Genuity Group Inc., Needham & Company LLC, Oppenheimer Holdings Inc., StockNews.com, and TheStreet.
View the latest analyst ratings for STAA.

What is the current price target for STAAR Surgical?

0 Wall Street analysts have set twelve-month price targets for STAAR Surgical in the last year. Their average twelve-month price target is $101.67, suggesting a possible upside of 33.5%.
View the latest price targets for STAA.

What is the current consensus analyst rating for STAAR Surgical?

STAAR Surgical currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STAA will outperform the market and that investors should add to their positions of STAAR Surgical.
View the latest ratings for STAA.

How do I contact STAAR Surgical's investor relations team?

STAAR Surgical's physical mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier's listed phone number is (626) 303-7902 and its investor relations email address is [email protected] The official website for STAAR Surgical is www.staar.com. Learn More about contacing STAAR Surgical investor relations.